Frequent Coamplification and Cooperation between C-MYC and PVT1 Oncogenes Promote Malignant Pleural Mesothelioma
暂无分享,去创建一个
David C. Rice | Ignacio I. Wistuba | Barbara Mino | Milind B. Suraokar | I. Wistuba | A. Tsao | M. Suraokar | Jaime Rodriguez | D. Rice | Heather Y. Lin | E. Riquelme | Anne Tsao | Jaime Rodriguez | Erick Riquelme | B. Mino | D. Rice
[1] B. Price. Analysis of current trends in United States mesothelioma incidence. , 1997, American journal of epidemiology.
[2] B. Lanphear,et al. Latent period for malignant mesothelioma of occupational origin. , 1992, Journal of occupational medicine. : official publication of the Industrial Medical Association.
[3] Stephanie I. Davis,et al. Incidence and Descriptive Epidemiology of Mesothelioma in the United States, 1999–2002 , 2007, International journal of occupational and environmental health.
[4] F. Ardissone,et al. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[5] Wen-Lin Kuo,et al. Amplification of PVT1 Contributes to the Pathophysiology of Ovarian and Breast Cancer , 2007, Clinical Cancer Research.
[6] Ramon Silva Martins,et al. Malignant pleural mesothelioma. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.
[7] M. Rocchi,et al. Identification of a commonly amplified 4.3 Mb region with overexpression of C8FW, but not MYC in MYC-containing double minutes in myeloid malignancies. , 2004, Human molecular genetics.
[8] G. Evan,et al. The apoptosis endonuclease and its regulation. , 1992, Seminars in immunology.
[9] L. You,et al. Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells. , 2011, Biochemical and biophysical research communications.
[10] A. Churg,et al. Changing trends in US mesothelioma incidence , 2004, Occupational and Environmental Medicine.
[11] M. Carbone,et al. The pathogenesis of mesothelioma. , 2006, Seminars in diagnostic pathology.
[12] Chi V. Dang,et al. The interplay between MYC and HIF in cancer , 2008, Nature Reviews Cancer.
[13] Kathryn A. O’Donnell,et al. The c-Myc target gene network. , 2006, Seminars in cancer biology.
[14] G. Ceresoli,et al. Advances in the biology of malignant pleural mesothelioma. , 2011, Cancer treatment reviews.
[15] M. Malumbres,et al. Physiological relevance of cell cycle kinases. , 2011, Physiological reviews.
[16] V. Rusch,et al. A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas. , 1998, Cancer research.
[17] M. Fried,et al. The DNA region around the c-myc gene and its amplification in human tumour cell lines. , 1994, Oncogene.
[18] Gerard I. Evan,et al. Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.
[19] R. Stephens,et al. The Identification of MicroRNAs in a Genomically Unstable Region of Human Chromosome 8q24 , 2008, Molecular Cancer Research.
[20] John M. Sedivy,et al. c-Myc Regulates Cyclin D-Cdk4 and -Cdk6 Activity but Affects Cell Cycle Progression at Multiple Independent Points , 1999, Molecular and Cellular Biology.
[21] Andrea Cocito,et al. Genomic targets of the human c-Myc protein. , 2003, Genes & development.
[22] Letizia Carramusa,et al. The PVT‐1 oncogene is a Myc protein target that is overexpressed in transformed cells , 2007, Journal of cellular physiology.
[23] R. Sutherland,et al. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells , 2014, BMC Cancer.
[24] Kathryn A. O’Donnell,et al. Activation of Transferrin Receptor 1 by c-Myc Enhances Cellular Proliferation and Tumorigenesis , 2006, Molecular and Cellular Biology.
[25] N. Caplen,et al. Pvt1-encoded microRNAs in oncogenesis , 2008, Retrovirology.
[26] R. Sutherland,et al. c-Myc or Cyclin D1 Mimics Estrogen Effects on Cyclin E-Cdk2 Activation and Cell Cycle Reentry , 1998, Molecular and Cellular Biology.
[27] J. Cleveland,et al. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. , 1991, Oncogene.
[28] K. Coombes,et al. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. , 2011, Cancer research.
[29] J. Bishop,et al. Identification of a human transcription unit affected by the variant chromosomal translocations 2;8 and 8;22 of Burkitt lymphoma. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[30] Derek Y. Chiang,et al. The landscape of somatic copy-number alteration across human cancers , 2010, Nature.
[31] H. Pass,et al. Simian virus 40-like DNA sequences in human pleural mesothelioma. , 1994, Oncogene.
[32] J. M. Adams,et al. Chromosome 8 breakpoint far 3′ of the c‐myc oncogene in a Burkitt's lymphoma 2;8 variant translocation is equivalent to the murine pvt‐1 locus. , 1986, The EMBO journal.
[33] T. Möröy,et al. Miz1 Is Required for Early Embryonic Development during Gastrulation , 2003, Molecular and Cellular Biology.
[34] Kerstin B. Meyer,et al. A Functional Variant at a Prostate Cancer Predisposition Locus at 8q24 Is Associated with PVT1 Expression , 2011, PLoS genetics.